HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

insulin detemir (Levemir)

Subscribe to New Research on insulin detemir

Also Known As:

Levemir; 12C-Lys(B29)-DB30I; B29-tetradecanoyl-Lys-B30-des-Ala-insulin; NN 304; NN-304; NN304; basal insulin detemir; des-(B30)-insulin, Lys(B29)-tetradecanoyl-; insulin, tetradecanoyl-Lys(B29)-des-Ala(B30)-; insulin, tetradecanoyllysyl(B29)-desalanyl(B30)-

Networked: 190 relevant articles (21 outcomes, 61 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	SOLVE Study Group: 7 articles (05/2014 - 07/2012)
2.	Svendsen, Anne Louise: 6 articles (05/2014 - 09/2011)
3.	Clauson, Per: 5 articles (01/2013 - 06/2006)
4.	Sreenan, S: 5 articles (04/2009 - 03/2007)
5.	Koenen, C: 5 articles (03/2008 - 03/2007)
6.	Hermansen, Kjeld: 4 articles (09/2011 - 06/2006)
7.	Dornhorst, A: 4 articles (04/2009 - 03/2007)
8.	Lüddeke, H-J: 4 articles (04/2008 - 03/2007)
9.	Caputo, S: 3 articles (12/2015 - 12/2012)
10.	Pan, Changyu: 3 articles (07/2015 - 05/2014)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 05/01/2014 - "Once-daily insulin detemir therapy was safe and effective, and rates of hypoglycemia were low. " 09/01/2009 - "Twelve weeks of treatment with insulin detemir improved glycemic control and reduced hypoglycemia in children with type 1 diabetes. " 08/01/2008 - "Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes." 05/01/2014 - "The aim of the present study was to identify demographic and treatment factors that were predictive of hypoglycemia in a large cohort of type 2 diabetic patients initiating insulin detemir. " 11/01/2011 - "The safety results of this study showed that 26 weeks of treatment with insulin detemir was associated with a very low rate of SADRs (only 14 events), which mainly consisted of hypoglycemia (78%, of which 42% were major hypoglycemia). "
2.	Weight Gain 04/01/2011 - "Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir." 12/01/2009 - "Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes." 09/01/2004 - "Studies of insulin detemir in basal-bolus regimens in type I and type II diabetes have shown significantly less weight gain compared with NPH. " 01/01/2013 - "Overall, patients with poorly controlled T2DM achieved significant reductions in HbA1c after initiation of once-daily insulin detemir therapy, without weight gain. " 01/01/2013 - "As no significant differences in HbA1c were observed between the two treatment arms, the model was based on significant differences in favour of insulin detemir in frequency of hypoglycaemia (Rate-Ratio = 0.52; CI = 0.44-0.61) and weight gain (Δ = 0.9 kg). "
3.	Type 2 Diabetes Mellitus (MODY) 06/01/2014 - "This sub-analysis of the A1chieve study aimed to examine the safety and efficacy of insulin detemir (IDet) initiation over 24 weeks in relation to baseline body mass index (BMI) in people with type 2 diabetes mellitus (T2DM). " 12/01/2012 - "Evaluate the safety and efficacy of once-daily insulin detemir initiated in routine clinical practice in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycaemic agents (OHAs). " 12/01/2015 - "SOLVE™ was a 24-week international observational study conducted in 10 countries (including Italy) for the evaluation of the safety and effectiveness of once-daily insulin detemir as add-on therapy in patients with type 2 diabetes mellitus (T2DM) already treated with one or more OADs. " 06/01/2014 - "Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve study." 04/01/2014 - "SOLVE is a 24-week, multinational observational study of insulin detemir initiation in patients with type 2 diabetes mellitus treated with one or more OADs. "
4.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/01/2013 - "To assess the efficacy and safety of insulin detemir administered once vs. twice daily in children and adolescents with type 1 diabetes mellitus. " 04/01/2008 - "This report describes a patient with a type 1 diabetes mellitus who develops a lipoatrophy induced by insulin detemir. " 08/01/2015 - "Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus." 10/01/2014 - "The efficacy and safety of insulin degludec (IDeg) was compared with insulin detemir (IDet), both administered once daily (OD) as basal treatment in participants with type 1 diabetes mellitus (T1DM). " 11/01/2011 - "Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus."
5.	Body Weight (Weight, Body) 09/01/2013 - "Mean body weight decreased overall by -0.4 ± 4.0 kg and blood pressure, lipid profiles, and self-reported quality of life improved over 24 weeks for all people starting treatment with insulin detemir. " 05/01/2007 - "These data confirm the short-term safety and efficacy of insulin detemir +/- OADs in a real-world scenario and support the findings of randomized controlled clinical trials with insulin detemir, including its limited effects on body weight." 03/01/2003 - "Body weight was significantly lower with insulin detemir at the end of the trial (P < 0.001). " 01/01/2012 - "Treatment with insulin detemir for 6 months resulted in substantial benefits, including reduced HbA(1c), FPG and body weight, and improvements in nocturnal quality of life, without increasing hypoglycaemia." 01/01/2011 - "Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats."

Related Drugs and Biologics

1.	NPH Insulin
2.	Insulin (Novolin)
3.	glargine (insulin glargine)
4.	Glucose (Dextrose)
5.	insulin aspart (NovoLog)
6.	Blood Glucose (Blood Sugar)
7.	Long-Acting Insulin (Insulin, Long Acting)
8.	Hypoglycemic Agents (Hypoglycemics)
9.	Serum Albumin
10.	insulin detemir (Levemir)

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Injections
3.	Intravenous Infusions
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)